nach oben

Erschienen in:

10.07.2020 | Original article

Predictors of respiratory decline in myotonic dystrophy type 1 (DM1): a longitudinal cohort study

verfasst von: Marco Mazzoli, Alessandra Ariatti, Giancarlo Garuti, Virginia Agnoletto, Riccardo Fantini, Alessandro Marchioni, Giuliana Galassi

Erschienen in: Acta Neurologica Belgica | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

We studied 33 patients affected by juvenile and adult myotonic dystrophy type 1 (DM1). The aim of the study was to assess clinical and laboratory parameters that could predict the requirement of noninvasive ventilation (NIV) in DM1. Secondary outcome was to assess the interplay between genetic profile, muscle impairment severity and presence of cardiac comorbidities.Patients with genetic diagnosis of DM1 were recruited. An abnormal trinucleotide repeat (CTG) expansion of dystrophy protein kinase gene (DMPK) on chromosome 19q13.3 was the prerequisite for inclusion. The number of triplet repeats was measured in genomic DNA to classify subjects. A multidisciplinary team evaluated the patients every 6–8 months up to 18 years with serial cardiological and respiratory function assessments. Neurological progression was monitored using a validated DM1-specific rating scale (MIRS). Independent variables considered for the study outcomes were gender, genetic status, age of presentation, MIRS scores, and results of pulmonary function tests (PFTs).Patients were 17 males (51.5%) and 16 females (48.5%). 16 cases were younger than mean age of 31.4 years, the remaining 17 were up to 65. 12 subjects (36.4%) underwent NIV during follow up. Cardiac comorbidities were detected in 63.6% of cases and in 91% of patients in NIV. Among PFTs, forced vital capacity (FVC) was a reliable indicator of respiratory decline. FVC values were significantly associated with clinical muscle severity assessed by MIRS.Severity of muscular impairment, CTG expansion size, age and presence of cardiac comorbidities predict respiratory impairment in DM1

Nur mit Berechtigung zugänglich

Bouchard J-P, Cossette L, Bassez G, Puymirat J (2015) Natural history of skeletal muscle involvement in myotonic dystrophy type 1: a retrospective study in 204 cases. J Neurol 262:285–293. https://doi.org/10.1007/s00415-014-7570-xCrossRefPubMed

Boussaïd G, Wahbi K, Laforet P et al (2018) Genotype and other determinants of respiratory function in myotonic dystrophy type 1. Neuromuscul Disord 28:222–228. https://doi.org/10.1016/j.nmd.2017.12.011CrossRefPubMed

Contardi S, Pizza F, Falzone F et al (2012) Development of a disability scale for myotonic dystrophy type 1: functional disability scale for DM1 patients. Acta Neurol Scand 125:431–438. https://doi.org/10.1111/j.1600-0404.2011.01587.xCrossRefPubMed

Dogan C, De Antonio M, Hamroun D et al (2016) Gender as a modifying factor influencing myotonic dystrophy type 1 phenotype severity and mortality: a nationwide multiple databases cross-sectional observational study. PLoS ONE 11:e0148264. https://doi.org/10.1371/journal.pone.0148264CrossRefPubMedPubMedCentral

Gagnon C, Chouinard MC, Laberge L et al (2010) Health supervision and anticipatory guidance in adult myotonic dystrophy type 1. Neuromuscul Disord 20:847–851. https://doi.org/10.1016/j.nmd.2010.08.006CrossRefPubMed

Mahadevan M, Tsilfidis C, Sabourin L et al (1992) Myotonic dystrophy mutation: an unstable CTG repeat in the 3’ untranslated region of the gene. Science 255:1253–1255. https://doi.org/10.1126/science.1546325CrossRefPubMed

Meola G (2013) Clinical aspects, molecular pathomechanisms and management of myotonic dystrophies. Acta Myol 32:154–165 (PMID: 24803843)PubMedPubMedCentral

Thornton CA (2014) Myotonic dystrophy. Neurol Clin 32:705–719. https://doi.org/10.1016/j.ncl.2014.04.011CrossRefPubMedPubMedCentral

Gagnon C, Petitclerc É, Kierkegaard M et al (2018) A 9-year follow-up study of quantitative muscle strength changes in myotonic dystrophy type 1. J Neurol 265:1698–1705. https://doi.org/10.1007/s00415-018-8898-4CrossRefPubMed

10.

Mathieu J, Boivin H, Meunier D et al (2001) Assessment of a disease-specific muscular impairment rating scale in myotonic dystrophy. Neurology 56:336–340. https://doi.org/10.1212/WNL.56.3.336CrossRefPubMed

11.

Turner C, Hilton-Jones D (2014) Myotonic dystrophy: diagnosis, management and new therapies. Curr Opin Neurol 27:599–606. https://doi.org/10.1097/WCO.0000000000000128CrossRefPubMed

12.

Udd B, Krahe R (2012) The myotonic dystrophies: molecular, clinical, and therapeutic challenges. Lancet Neurol 11:891–905. https://doi.org/10.1016/S1474-4422(12)70204-1CrossRefPubMed

13.

Hammarén E, Kjellby-Wendt G, Lindberg C (2015) Muscle force, balance and falls in muscular impaired individuals with myotonic dystrophy type 1: a five-year prospective cohort study. Neuromuscul Disord 25:141–148. https://doi.org/10.1016/j.nmd.2014.11.004CrossRefPubMed

14.

Ashizawa T, Gagnon C, Groh WJ et al (2018) Consensus-based care recommendations for adults with myotonic dystrophy type 1. Neurol Clin Pract 8:507–520. https://doi.org/10.1212/CPJ.0000000000000531CrossRefPubMedPubMedCentral

15.

Petitclerc É, Hébert LJ, Mathieu J et al (2018) Relationships between lower limb muscle strength impairments and physical limitations in DM1. J Neuromuscul Dis 5:215–224. https://doi.org/10.3233/JND-170291CrossRefPubMed

16.

Wahbi K, Porcher R, Laforêt P et al (2018) Development and validation of a new scoring system to predict survival in patients with myotonic dystrophy type 1. JAMA Neurol 75:573. https://doi.org/10.1001/jamaneurol.2017.4778CrossRefPubMedPubMedCentral

17.

Boussaïd G, Lofaso F, Santos DB et al (2016) Factors influencing compliance with non-invasive ventilation at long-term in patients with myotonic dystrophy type 1: a prospective cohort. Neuromuscul Disord 26:666–674. https://doi.org/10.1016/j.nmd.2016.07.014CrossRefPubMed

18.

Naddaf E, Milone M (2017) Hereditary myopathies with early respiratory insufficiency in adults: respiratory failure myopathies. Muscle Nerve 56:881–886. https://doi.org/10.1002/mus.25602CrossRefPubMed

19.

Hermans MCE, Pinto YM, Merkies ISJ et al (2010) Hereditary muscular dystrophies and the heart. Neuromuscul Disord 20:479–492. https://doi.org/10.1016/j.nmd.2010.04.008CrossRefPubMed

20.

Pfeffer G, Povitz M, Gibson GJ, Chinnery PF (2015) Diagnosis of muscle diseases presenting with early respiratory failure. J Neurol 262:1101–1114. https://doi.org/10.1007/s00415-014-7526-1CrossRefPubMed

21.

Poussel M, Thil C, Kaminsky P et al (2015) Lack of correlation between the ventilatory response to CO2 and lung function impairment in myotonic dystrophy patients: Evidence for a dysregulation at central level. Neuromuscul Disord 25:403–408. https://doi.org/10.1016/j.nmd.2015.02.006CrossRefPubMed

22.

Shneerson JM, Simonds AK (2002) Noninvasive ventilation for chest wall and neuromuscular disorders. Eur Respir J 20:480–487. https://doi.org/10.1183/09031936.02.00404002CrossRefPubMed

23.

Thil C, Agrinier N, Chenuel B, Poussel M (2017) Longitudinal course of lung function in myotonic dystrophy type 1. Muscle Nerve 56:816–818. https://doi.org/10.1002/mus.25604CrossRefPubMed

24.

Sansone VA, Gagnon C (2015) 207th ENMC Workshop on chronic respiratory insufficiency in myotonic dystrophies: Management and implications for research, 27–29 June 2014, Naarden, The Netherlands. Neuromuscul Disord 25:432–442. https://doi.org/10.1016/j.nmd.2015.01.011CrossRefPubMed

25.

Hawkins AM, Hawkins CL, Abdul Razak K et al (2019) Respiratory dysfunction in myotonic dystrophy type 1: a systematic review. Neuromuscul Disord 29:198–212. https://doi.org/10.1016/j.nmd.2018.12.002CrossRefPubMed

26.

Monteiro R, Bento J, Gonçalves MR et al (2013) Genetics correlates with lung function and nocturnal ventilation in myotonic dystrophy. Sleep Breath 17:1087–1092. https://doi.org/10.1007/s11325-013-0807-6CrossRefPubMed

27.

Rossi S, Della Marca G, Ricci M et al (2019) Prevalence and predictor factors of respiratory impairment in a large cohort of patients with Myotonic Dystrophy type 1 (DM1): a retrospective, cross sectional study. J Neurol Sci 399:118–124. https://doi.org/10.1016/j.jns.2019.02.012CrossRefPubMed

28.

Vivekananda U, Turner C (2019) A model to predict ventilator requirement in myotonic dystrophy type 1. Muscle Nerve 59:683–687. https://doi.org/10.1002/mus.26471CrossRefPubMed

29.

Bogaard JM, van der Meché FG, Hendriks I, Verves C (1992) Pulmonary function and resting breathing pattern in myotonic dystrophy. Lung 170:143–153. https://doi.org/10.1007/bf00174317CrossRefPubMed

30.

Bégin P, Mathieu J, Almirall J, Grassino A (1997) Relationship between chronic hypercapnia and inspiratory-muscle weakness in myotonic dystrophy. Am J Respir Crit Care Med 156:133–139. https://doi.org/10.1164/ajrccm.156.1.9509041CrossRefPubMed

31.

Bucci E, Testa M, Licchelli L et al (2018) A 34-year longitudinal study on long-term cardiac outcomes in DM1 patients with normal ECG at baseline at an Italian clinical centre. J Neurol 265:885–895. https://doi.org/10.1007/s00415-018-8773-3CrossRefPubMed

32.

Chong-Nguyen C, Wahbi K, Algalarrondo V et al (2017) Association between mutation size and cardiac involvement in myotonic dystrophy type 1: an analysis of the DM1-heart registry. Circ Cardiovasc Gen 10(3):e001526. https://doi.org/10.1161/CIRCGENETICS.116.001526CrossRef

33.

Lau JK, Sy RW, Corbett A, Kritharides L (2015) Myotonic dystrophy and the heart: a systematic review of evaluation and management. Int J Cardiol 184:600–608. https://doi.org/10.1016/j.ijcard.2015.03.069CrossRefPubMed

34.

Wahbi K, Babuty D, Probst V et al (2017) Incidence and predictors of sudden death, major conduction defects and sustained ventricular tachyarrhythmias in 1388 patients with myotonic dystrophy type 1. Eur Heart J 38:751–758. https://doi.org/10.1093/eurheartj/ehw569CrossRefPubMed

35.

Petri H, Vissing J, Witting N et al (2012) Cardiac manifestations of myotonic dystrophy type 1. Int J Cardiol 160:82–88. https://doi.org/10.1016/j.ijcard.2011.08.037CrossRefPubMed

36.

Lund M, Diaz LJ, Ranthe MF et al (2014) Cardiac involvement in myotonic dystrophy: a nationwide cohort study. Eur Heart J 35:2158–2164. https://doi.org/10.1093/eurheartj/ehu157CrossRefPubMed

37.

Kaminsky P, Brembilla-Perrot B, Pruna L et al (2013) Age, conduction defects and restrictive lung disease independently predict cardiac events and death in myotonic dystrophy. Int J Cardiol 162:172–178. https://doi.org/10.1016/j.ijcard.2011.05.070CrossRefPubMed

38.

Priori SG, Blomstrom-Lundqvist C, Mazzanti A et al (2015) 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J 36(41):2793–2867. https://doi.org/10.1093/eurheartj/ehv316CrossRefPubMed

39.

Ponikowski P, Voors AA, Anker DS et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37:2129–2200. https://doi.org/10.1093/eurheartj/ehw128CrossRef

40.

Kirchhof P, Benussi S, Kotecha D et al (2016) 2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC Endorsed by the European Stroke Organisation (ESO). Eur Heart J 37(38):2893–2962. https://doi.org/10.1093/eurheartj/ehw210CrossRefPubMed

41.

Mandrioli J, Ferri L, Fasano A et al (2018) Cardiovascular diseases may play a negative role in the prognosis of amyotrophic lateral sclerosis. Eur J Neurol 25:861–868. https://doi.org/10.1111/ene.13620CrossRefPubMed

Titel: Predictors of respiratory decline in myotonic dystrophy type 1 (DM1): a longitudinal cohort study
verfasst von: Marco Mazzoli
Alessandra Ariatti
Giancarlo Garuti
Virginia Agnoletto
Riccardo Fantini
Alessandro Marchioni
Giuliana Galassi
Publikationsdatum: 10.07.2020
Verlag: Springer International Publishing
Erschienen in: Acta Neurologica Belgica / Ausgabe 1/2021
Print ISSN: 0300-9009
Elektronische ISSN: 2240-2993
DOI: https://doi.org/10.1007/s13760-020-01425-z

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

Assessment of delayed diagnosis and treatment in multiple sclerosis patients during 1990–2016

A fatal case of glycine receptor antibody-mediated autoimmune encephalitis

The efficacy of magnesium oxide and sodium valproate in prevention of migraine headache: a randomized, controlled, double-blind, crossover study

A novel single-base mutation mimicking exon deletion of MLPA in symptomatic Duchenne muscular dystrophy carrier

Adult-onset congenital central hypoventilation syndrome due to PHOX2B mutation